Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Cofact is a non-activated, heparin-free, four-factor prothrombin complex concentrate (4F-PCC) derived from human plasma. It contains the coagulation factors II, VII, IX, and X, as well as the proteins C and S. It is primarily used for the rapid reversal of anticoagulation induced by vitamin K antagonists (VKAs) or direct factor Xa inhibitors, such as apixaban and rivaroxaban, in cases of major bleeding or the need for urgent surgery. Unlike some other PCC formulations, Cofact is formulated without heparin, which may improve clot stability against fibrinolytic breakdown. The product works by restoring thrombin generation, which is suppressed by anticoagulants.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Cofact.